5-(4-(7-T-丁基-6-羟基-2-甲基色满-2-基甲氧基)苄基)噻唑烷-2,4-二酮 | 97323-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 5-(4-(7-T-丁基-6-羟基-2-甲基色满-2-基甲氧基)苄基)噻唑烷-2,4-二酮
• 中文别名: 3-[(2,4-二羟基-3,3-二甲基丁酰)氨基]-2-磷羧基丙酸
• 英文名称: 5-[4-(7-t-Butyl-6-hydroxy-2-methylchroman-2-yl-methoxy)benzyl ]thiazolidine-2,4-dione
• 英文别名: 5-[4-(6-hydroxy-2-methyl-7-t-butylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione；5-[4-(6-Hydroxy-2-methyl-7-t-butylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione；5-(4-(7-t-Butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione；5-[[4-[(7-tert-butyl-6-hydroxy-2-methyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 97323-07-4
• 化学式: C₂₅H₂₉NO₅S
• 分子量: 455.575
• InChiKey: KMCXNGXUURGATQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-acetoxy-2-(4-aminophenoxymethyl)-7-t-butyl-2-methylchroman 在 copper(I) oxide 、 盐酸 、 溶剂黄146 、 sodium nitrite 作用下， 生成 5-(4-(7-T-丁基-6-羟基-2-甲基色满-2-基甲氧基)苄基)噻唑烷-2,4-二酮
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022

文献信息

• Thiazolidine derivatives, their preparation and use
  申请人：Sankyo Company, Limited

  公开号：US05104888A1

  公开（公告）日：1992-04-14

  Compounds of formula (I): ##STR1## (in which R.sup.1 -R.sup.7 are hydrogen or various organic groups, n is 1-10, Ar is an aromatic group, U is CH.sub.2 or a carbon atom doubly bonded to either one of its adjacent carbons, and W is >CH.sub.2, >C.dbd.O, >CHOH, >C.dbd.NOH or various derivatives thereof) have the ability to lower the levels of blood lipid peroxides and blood sugars and to inhibit the activity of aldose reductase; they may be used therapeutically for these purposes.

  公式(I)的化合物：##STR1##（其中R.sup.1 -R.sup.7是氢或各种有机基团，n是1-10，Ar是芳香族基团，U是CH.sub.2或一个碳原子与任一相邻的碳原子双键连接，W是>CH.sub.2，>C.dbd.O，>CHOH，>C.dbd.NOH或其各种衍生物）具有降低血脂过氧化物和血糖水平以及抑制醛糖还原酶活性的能力；它们可以用于这些目的的治疗。
• Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0783888A1

  公开（公告）日：1997-07-16

  Compounds of formula (I): [where R1, R2, R4 and R5 are hydrogen or alkyl and R3 is hydrogen, alkyl or various organic groups] are effective against osteoporosis at doses at which they also effectively control diabetes.

  式(I)化合物： [其中 R1、R2、R4 和 R5 为氢或烷基，R3 为氢、烷基或各种有机基团]可有效防治骨质疏松症，其剂量也可有效控制糖尿病。
• Treatment and prophylaxis of pancreatitis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0796618A1

  公开（公告）日：1997-09-24

  Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.

  胰岛素增敏剂，尤其是噻唑烷二酮化合物，如曲格列酮，可用于治疗和预防胰腺炎。
• Composition for use in the treatment and prevention of hyperuricemia
  申请人：Sankyo Company Limited

  公开号：EP0919232A1

  公开（公告）日：1999-06-02

  Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

  曲格列酮等胰岛素敏感性增强剂具有治疗和/或预防高尿酸血症的能力，因此可用于痛风、尿路结石、高尿酸血症肾病和莱希-尼汉综合征等疾病的治疗或预防。
• REMEDY FOR AUTOIMMUNE DISEASES
  申请人：Sankyo Company, Limited

  公开号：EP0953355A1

  公开（公告）日：1999-11-03

  A preventive or therapeutic agent for autoimmune diseases (excluding type I diabetes) contaning an insulin resistance improving substance as an active ingredient.

  一种预防或治疗自身免疫性疾病（I 型糖尿病除外）的制剂，含有一种改善胰岛素抵抗的物质作为活性成分。